Fig. 4From: Long-term reductions in disease impact in patients with chronic migraine following preventive treatment with eptinezumabMIDAS total score ± standard error at baseline, Week 12, Week 84, and Week 104: A total safety population and subgroup with very severe MIDAS disability*, and B patients with < 50%, 50‒74%, or ≥ 75% HRR at Week 12. HRR, headache responder rate assessed by MIDAS; MIDAS, Migraine Disability Assessment. *Level of disability based on MIDAS total score: little or no disability (0–5), mild disability (6–10), moderate disability (11–20), severe disability (21–40), very severe disability (41–270)Back to article page